IVF is a process of fertilization where an egg is combined with sperm outside the body, in vitro ("in glass”). In vitro fertilization (IVF) is a sophisticated set of treatments intended to improve fertility, avoid genetic issues, and aid in child conception. It is used to address infertility. The main types of cycles in IVF services markets are fresh IVF cycles (non-donor), thawed IVF cycles (non-donor), and donor egg IVF cycles. When an IVF cycle is completed utilizing eggs and embryos that have never been frozen, it is referred to as a fresh IVF cycle. After the eggs are extracted, they are fertilized in the lab with semen. The different service providers include fertility clinics, hospitals, surgical centres, clinical research institutes and is used in various sectors such as fertility clinics, hospitals, and other settings. The IVF services market research report is one of a series of new reports from The Business Research Company that provides IVF services market statistics, including IVF services industry global market size, regional shares, competitors with a IVF services market share, detailed IVF services market segments, market trends and opportunities, and any further data you may need to thrive in the IVF services industry. This IVF services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global ivf services market size will grow from $15.38 billion in 2022 to $17.13 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global ivf services market size is expected to grow to $25.27 billion in 2027 at a CAGR of 10.2%. The rising infertility rate contributed to the growth of the in vitro fertilization (IVF) services market. Infertility is known as the inability to conceive within 12 months. According to the US Department of Health and Human Services, around 12 to 13 couples in 100 have a problem in conceiving. Moreover, according to the Indian Journal of Community Medicine, 15 to 20 million infertility cases are in India alone. The rising infertility rate made people resort to IVF services contributing to the growth of the market. The high cost of IVF services limits the in-vitro fertilization (IVF) services market. For instance, the cost of a basic IVF package ranges from $4,700 to $20,000, and the average price in the USA is around $12,000. The total cost of a single IVF cycle can range between $8,000 to $30,000. According to FertilityIQ, the cost of IVF services was around $22,000. In emerging economies like India, the cost of IVF services ranges from INR 70,000 to INR 300,000. The high cost of IVF services makes it unavailable to low- and middle-income populations negatively affecting the IVF services' market growth. Platelet-rich plasma (PRP) is the latest technique increasingly used for improving IVF success rate in patients with recurrent implantation failures. PRP is used alongside fertility treatments like IVF to improve egg quality, uterine lining thickness and endometrial receptivity, and the treatment is primarily for recurrent implantation failure over multiple IVF cycles. According to an article published by the Journal of Assisted Reproduction and Genetics, women treated with PRP experienced a significant improvement in Follicle-Stimulating Hormone (FSH), Anti-Müllerian Hormone (AMH), and Antral Follicle Count (AFC) and help improve fertility. In December 2020, Fresenius Helios, a Germany-based healthcare company acquired Eugin Group for $ 195.98 million (€160 million). The acquisition expands Fresenius Helios's global network of fertility clinics, providing tremendous growth and consolidation potential. Eugin Group is a Spain-based company that provides IVF services. Major players in the IVF services market are Ambroise Par Group, amedes MVZ Köln GmbH, AMP Centre St Roch, AVA Clinic Scanfert, Bangkok IVF center, Betamedics, Bloom Fertility and Healthcare, Bourn Hall Fertility Centre, Biofertility Centre and Chelsea and Westminster Hospital (Assisted Conception Unit). Western Europe was the largest region in the IVF services market in 2022. North America was the second largest region in global IVF services market. The regions covered in the global IVF services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the IVF services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The IVF services market includes revenues earned by entities by providing services such as conventional insemination services, and intracytoplasmic sperm injection services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global IVF services market is segmented - 1) By Cycle Type: Fresh IVF Cycles(Non-donor), Thawed IVF Cycles(Non-donor), Donor Egg IVF Cycles 2) By Service Provider: Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes 3) By End User: Fertility Clinics, Hospitals & Other Settings

Prenatal testing and newborn screening tests are diagnostic tests to detect any possible birth defects that may be there in the baby. These are useful in determining the health of the baby. The main diagnostic types of prenatal testing and newborn screening are non-invasive and invasive. Invasive diagnostic testing necessitates puncturing the skin or invading the body. A few examples include blood testing, biopsies, and colonoscopies. The different technologies include screening technology, diagnostic technology and is used in various sectors such as hospitals, and diagnostic centres. The prenatal testing and newborn screening tests market research report is one of a series of new reports from The Business Research Company that provides prenatal testing and newborn screening tests market statistics, including prenatal testing and newborn screening tests industry global market size, regional shares, competitors with prenatal testing and newborn screening tests market share, detailed prenatal testing and newborn screening tests market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal testing and newborn screening tests industry. This prenatal testing and newborn screening tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global prenatal testing & newborn screening market grew from $5.04 billion in 2022 to $5.65 billion in 2023 at a compound annual growth rate (CAGR) of 12.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The prenatal testing & newborn screening market is expected to grow from $8.87 billion in 2027 at a CAGR of 11.9%. The high prevalence of genetic diseases in infants contributed to the growth of the prenatal testing and newborn screening market. According to the World Health Organization, genetic disease includes diseases such as Thalassemia, Sickle Cell Anaemia, Haemophilia, Cystic Fibrosis, Tay Sachs disease, Fragile X Syndrome, Huntington’s disease. The sickle cell anaemia is one of the genetic diseases that affects millions throughout the world, and the disease is particularly common among people whose ancestors are from Africa, America, Cuba, Central America, Saudi Arabia, and India. According to data published in 2020 by the Centres for Disease Control and Prevention, a national public health agency of the United States, 5,568 babies were affected by Trisomy 21 (Down syndrome), 1,187 babies were affected by Trisomy 18 (Edwards syndrome), and 531 babies were affected by Trisomy 13 (Patau syndrome). The high prevalence of genetic diseases in infants boosted the demand for prenatal testing and newborn screening market. Growth of the prenatal testing and newborn screening market may be hampered by the relatively low healthcare access in most developing countries, compared to the developed nations. For instance, in India, there were only about 1.9 million hospital beds for 1.33 billion people, as of 2020. Low access to healthcare services and the lack of sufficient hospitals and healthcare professionals harmed market growth in many developing nations. Moreover, low disposable income in many countries further lowers the access to healthcare services, thus negatively hampering the growth of the prenatal testing and newborn screening market. The use of machine learning and artificial intelligence is gradually gaining popularity in the prenatal testing and newborn screening market. Artificial intelligence (AI) is the simulation of human intelligence in machines. Machine learning is a part of AI. Machine learning and AI help companies in the prenatal testing and newborn screening market to conduct a detailed analysis of all relevant data, provide insights about different diseases, and offer a more accurate evaluation of tissue samples. For instance, In September 2021, Sema4, a US-based AI-driven genomic and clinical data intelligence platform company, launched Sema4 Elements. Sema4 Elements are genetic solutions that are information-driven, digital tools for patients and providers, and services that let doctors manage patients holistically throughout their journeys with reproductive and generational health, using artificial intelligence. In March 2020, Thermo Fisher Scientific Inc. announced its decision to acquire Qiagen for $11.5 billion. Thermo Fisher has a specialty diagnostics capability, that includes allergy, autoimmunity, transplant diagnostics, and oncology testing. The acquisition is expected to complement Thermo Fisher’s genetic analysis and bioscience capabilities. Qiagen is a Germany-based genetic tester that was founded in 1984 and operates more than 35 offices in over 25 countries. Major players in the prenatal testing and newborn screening market are PerkinElmer, Progenity, Laboratory Corporation of America Holdings (Sequenom), Natera, Invitae, Centogene, Cradle Genomics, Roche Diagnostics, Quest Diagnostics and Baebies. North America was the largest region in the prenatal testing and newborn screening market in 2022. Western Europe was the second largest region in the global prenatal testing and newborn screening market. The regions covered in the global prenatal testing and newborn screening tests market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the prenatal testing and newborn screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The prenatal testing and newborn screening tests market includes revenues earned by entities by providing blood test services, hearing test services, CCHD screening tests, and non-invasive tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global prenatal testing & newborn screening market is segmented - 1) By Diagnostic Type: Non-Invasive, Invasive 2) By Technology: Screening Technology, Diagnostic Technology 3) By End user: Hospitals, Diagnostic centers

Fertility drugs refer to a term used to describe medications that cause your body to release hormones that regulate or prompt ovulation, or the release of an egg from your ovary. The main types of fertility drugs are prescription fertility drugs and over-the-counter fertility drugs. The drugs are administered orally, intravenously, subcutaneously, and intramuscularly to male and female patients. Subcutaneous administration refers to the process of injecting the drugs into the fatty tissue just beneath the skin. The drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The fertility drugs market research report is one of a series of new reports from The Business Research Company that provides fertility drugs market statistics, including fertility drugs industry global market size, regional shares, competitors with a fertility drugs market share, detailed fertility drugs market segments, market trends and opportunities, and any further data you may need to thrive in the fertility drugs industry. This fertility drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global drugs for infertility market size will grow from $2.93 billion in 2022 to $3.03 billion in 2023 at a compound annual growth rate (CAGR) of 3.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drugs for infertility market size is expected to grow to $3.30 billion in 2027 at a CAGR of 2.1%. The growth of the market for fertility drugs is driven by the increasing rates of infertility across the globe. Infertility is the inability to conceive after trying for 12 consecutive months. Fertility drugs are widely used to treat infertility in both men and women. The rising rates of infertility are attributed to physiological problems, hormone problems, and lifestyle or environmental factors. To treat infertility problems in women, fertility drugs are used to regulate their ovulation cycles, which affects the sale of these drugs. For instance, in September 2020, according to the World Health Organization (WHO), a Switzerland-based international public health organization, millions of people in the world who are of reproductive age will struggle with infertility, which will also have an effect on their families and communities. Worldwide, it is estimated that 48 million couples and 186 million people struggle with infertility. Hence, the rising cases of infertility across the globe are increasing the demand for fertility drugs, resulting in the growth of the fertility drug market. The side effects caused due to fertility drugs restricted the growth of the fertility drugs market. Fertility drugs can result in permanent as well as temporary side effects. Temporary side effects include bloating, headache, breast tenderness, upset stomach, hot flashes, and mood swings whereas the permanent side effects include multiple pregnancies, and ovarian hyperstimulation syndrome (OHSS). OHSS is a condition where the ovaries enlarge with fluids and may become life-threatening if left untreated. For instance, the intake of Clomid (clomiphene citrate), a fertility drug for women, can result in OHSS along with abnormal vaginal/uterine bleeding, breast tenderness or discomfort, headache, nausea, vomiting, diarrhea, flushing, blurred vision, or other visual disturbances. The fear of potential side effects of fertility drugs restricts the growth of the fertility drugs market. The companies in the fertility drugs market are focusing on the launch of self- administration fertility solutions for advanced infertility treatment. The self- administration fertility solution makes it easier and less painful for women to self-administer daily injections. For example, in August 2021, Merck Specialities, the healthcare business of Merck in India, launched Pergoveris Pen for advanced infertility treatment in India. This launch aims to fulfill unmet medical needs by providing an improved, convenient, and ready-to-use combination treatment option for women with a severe follicle-stimulating hormone (FSH) and luteinizing hormone (LH) deficiency. The Pergoveris Pen is a combination of a freeze-dried powder and solvent, reducing the probability of reconstitution errors. As a result, Pergoveris delivers with more precision and, hence, is more accessible to self-administration by patients during infertility treatment. In January 2020, Evotec SE, a Germany-based pharmaceutical company specialising in drug discovery and development, announced strategic partnerships with Bayer AG, a pharmaceutical and biotechnology company pioneering in the discovery, development, manufacturing, and commercialization of drugs. Under this collaboration, to develop a new cure and multiple clinical candidates for the treatment of polycystic ovary syndrome together, both businesses will offer drug targets and a wide array of high-quality technological platforms. Major players in the fertility drugs market are Merck & Co., Ferring Pharmaceuticals, Bayer, Berlex Laboratories Inc., Janssen Pharmaceutical Inc., Pfizer, Novartis AG, Procter & Gamble Pharmaceutical, Zydus Pharma, LIVZON, Abbott, MSD, Sanofi S.A., Eli Lilly and Co., Serono, Inc., Novogyne Pharmaceuticals, and Takeda Pharmaceutical co. ltd. North America was the largest region in the fertility drugs market in 2022. The Middle East is expected to be the fastest-growing region in the global drugs for infertility market during the forecast period. The regions covered in the global fertility drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fertility drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The fertility drugs market consists of sales of clomiphene citrate, gonadotropins, and metformin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global fertility drugs market is segmented - 1) By Gender: Male, Female 2) By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular 3) By Type Of Drug: Prescription Fertility Drugs, Over-The-Counter Fertility drugs 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Fertility treatment is a medical treatment provided to a man or a woman to increase their chances of bearing an offspring. It is used to treat infertile patients. Hormone and ovulation-supporting medicines are frequently used in fertility treatments, sometimes in conjunction with minor surgical procedures. The main product types of fertility are reagents, and equipment. A reagent is a material or compound that is added to a system to produce a chemical reaction or to determine whether or not a reaction occurred. The treatments are performed on female and male in fertility clinics, hospitals, surgical centers, and clinical research institutes. The fertility treatment market research report is one of a series of new reports from The Business Research Company that provides fertility treatment market statistics, including fertility treatment industry global market size, regional shares, competitors with a fertility treatment market share, detailed fertility treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fertility treatment industry. This fertility treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global fertility treatments market grew from $15.26 billion in 2022 to $16.48 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The fertility treatments market is expected to grow from $22.77 billion in 2027 at a CAGR of 8.4%. The growth in the median age of first-time motherhood combined with change in lifestyle increased the difficulty of conceiving, increasing the demand for fertility treatment. The median age of first-time motherhood has increased all over the globe due to late marriages, contraceptive techniques, and an increase in the number of women who prioritize their careers over starting a family. In 2020, the average age of first-time mothers in America has risen from 21 to 26. Women in other developed countries are also deferring, with the typical first birth occurring at the age of 31 for new mothers. In this scenario, a growing number of women are opting for IVF treatments, which is expected to drive this market. The high cost and low success rate of In vitro fertilization (IVF) treatment is a major factor that limits the growth of the fertility treatments market. In vitro fertilization is a fertilization process in which an egg is fertilized with sperm outside the body, in vitro. In vitro fertilization (IVF) treatment costs differ in many countries due to the lack of refund policies. Moreover, insurance companies usually do not cover infertility treatments. According to the American society of reproductive medicine, in the USA, the average cost of an IVF cycle is $12,400 and the average cost of an IVF cycle using fresh embryos is $8,158 with a median cost at $7,500. The rate of success of IVF treatments is only 28% to 35%, which decreases with the increase in woman's age. For example, for women, the success rate is 32.2% under 35 and 1.9% for women aged over 44. Thus, the high cost and low success rate of IVF treatment restrict the growth of the fertility treatment market. Development of new techniques to treat infertility using a human’s body is a key trend in the fertility treatments market. INVOcell is an IVF alternative that uses the woman’s body to support fertilization, thus eliminating the cost of a laboratory incubator. The INVOcell device is placed with the eggs and sperm in the vaginal cavity, allowing for the stability of the natural environment, pH, and gas to help in fertilization. INVOcell, which is made in Medford, Massachusetts by INVO Bioscience, costs around $6,800 including medication. Although IVF generated more quality embryos, the birth rates between IVF and INVOcell are similar. According to the journal of assisted reproduction and genetics, 12 out of 20 women gave birth to 15 babies in IVF including three sets of twins and 11 out of 20 women gave birth to 16 babies in INVOcell group including five sets of twins. In August 2022, CCRM Fertlity, an American fertility treatment company, acquired Institute for Reproductive Medicine & Sciences (IRMS) for an undisclosed amount. The acquisition would add world class proprietary reproductive medicine offerings to the CCRM’s portfolio and expand its footprint across 11 major metropolitan areas with 34 locations across the US and Canada. Institute for Reproductive Medicine and Science (IRMS) is a US-based fertility research and treatment company having its presence in major metropolitan areas. Major players in the fertility treatment market are Apollo Hospitals Enterprise Ltd., Care Fertility Group, Genea Limited, The Johns Hopkins Health System Corp., Medicover Group, Monash IVF Group, Progyny Inc., Vitrolife, Carolinas Fertility Institute, OvaScience Inc., Xytex Cryo International, Merck KGaA, Cook Medical, CooperSurgical Inc., Instituto Bernabeu, INVO Bioscience, The Cooper Companies Inc., Virtus Health, CryoChoice LLC., Millendo Therapeutics Inc., FUJIFILM Irvine Scientific, LABOTECT GMBH, Fertility Focus, Olympus Corporation, Irvine Scientific sales Company Inc., and Ferring Pharmaceuticals. North America was the largest region in the fertility treatment market in 2022. Western Europe was the second largest region in the global fertility treatment market. The regions covered in the global fertility treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fertility treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The fertility treatment market includes revenues earned by entities by providing medicinal services, surgical services, and assisted services such as in vitro fertilization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global fertility treatments market is segmented - 1) By Product: Reagents, Equipment 2) By End-User: Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes 3) By Patient Type: Female, Male

Non-invasive prenatal testing is a test in which blood from the mother is drawn and tested for possible abnormalities in the patient. Non-invasive prenatal testing kits and equipment are used to diagnose genetic abnormalities, mainly chromosome defects, in fetuses in the first trimester of pregnancy. The non-invasive prenatal testing market consists of sales of non-invasive prenatal testing kits, instruments, and related services. Non-invasive prenatal testing kits and equipment are used to diagnose genetic abnormalities, mainly chromosome defects, in fetuses in the first trimester of pregnancy. Non-invasive prenatal testing includes ultrasound detection, fetal cells in maternal blood tests, cell-free DNA in maternal plasma tests, and biochemical screening tests. The main types of non-invasive prenatal testing are consumables, and instruments. Consumables are products that are used up or depleted throughout their use. The various instrument used are NGS systems, PCR instruments, microarrays, ultrasound devices, and others (centrifuges, UV systems, incubators, microscopes) and the different consumables include assay kits and reagents, disposables. The applications involve trisomy, microdeletion, genetics, Rh factor that are used by hospitals and diagnostic labs. The non-invasive prenatal testing market research report is one of a series of new reports from The Business Research Company that provides non-invasive prenatal testing market statistics, including non-invasive prenatal testing industry global market size, regional shares, competitors with a non-invasive prenatal testing market share, detailed non-invasive prenatal testing market segments, market trends and opportunities, and any further data you may need to thrive in the non-invasive prenatal testing industry. This non-invasive prenatal testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global non-invasive prenatal testing market will grow from $4.21 billion in 2022 to $4.84 billion in 2023 at a compound annual growth rate (CAGR) of 14.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global non-invasive prenatal testing market is expected to grow to $8.36 billion in 2027 at a CAGR of 14.7%. High incidence rate of Down syndrome is one major factor driving non-invasive prenatal testing (NIPT) market with increase in average maternal age which has led to a concern on the safety about the growth of the fetus. Down syndrome is a chromosomal condition that occurs when an error in cell division results in an extra chromosome 21 and can affect the fetus cognitive ability and physical growth. The NIPT screening tests do not harm the mother or baby, carries no risk of miscarriage as they are non-invasive, and can detect more than 99% of cases of Down syndrome. According to National Down Syndrome Society and Centres for Disease control and Prevention, in the USA, 1 in every 700 babies are born with Down syndrome and 80% of children with Down syndrome are born to older mothers. The increased risk of having babies with Down syndrome among older women drives the non-invasive prenatal testing market. The ethical hurdles in the non-invasive prenatal testing (NIPT) market have led to a range of ethical issues in terms of sex selection or aborting babies with chromosomal abnormality. Determining the sex of the fetus or knowing if the baby has an abnormality at an earlier stage led to abortions and resulted as an ethical issue which further led to strict regulations on using such devices. According to the official statistics provided by the UK government, a record 214,869 abortions were performed in the Englan and Wales in 2021 which was the highest sinch abortion became legal in 1967.. These hurdles will restrain the non-invasive prenatal testing market. Next-generation sequencing has increased the throughput, scalability, and speed, and further enables researchers to perform a wide range of applications and study biological systems at a higher level. Next-generation sequencing is a platform that has enabled the sequencing of thousands to millions of DNA molecules simultaneously. The manufacturers have introduced this technology to reduce the time and money required and optimizes the output to generate results regarding genome, and DNA testing. Major companies such as Illumina, Eurofins, Natera, Roche, and Annoroad have implemented this technology in non-invasive prenatal testing. CFDA (China Food and Drug Administration) has approved the medical instrument product registration of NGS instrument NextSeq 550AR produced by Annoroad. The non-invasive prenatal testing market is regulated by several regulations that are governed by multiple international and country-specific agencies. For instance, the US Food and Drug Administration (FDA) that issues Laboratory Developed Tests (LDTs) certification and Clinical Laboratory Improvement Amendments (CLIA) certification. The manufacturer needs to obtain a 510(k) premarket notification for in vitro diagnostic test. LDTs and CLIA certification are based on number of tests done during clinical trials. For example: For trisomy 21 (Down syndrome), there is an incidence of 1/1000. Given a target of 100 positive results, at least 100,000 samples would have to be tested to meet the requirements of a 510k. A 510k premarket notification demonstrates that the new product is at least as safe and effective as another legally-marketed device. It is mandatory for manufacturers to register a premarket notification before a new product can be certified as fit for market commercially. BioReference Laboratories, a New York-based medical laboratory company, acquired Ariosa's centralized laboratory prenatal testing business from Roche in August 2021.The acquisition will complement the current offerings of BioReference and help it improve its offerings. Ariosa Diagnostics is a US-based non-invasive prenatal screening business owned by Roche.  Major players in the non-invasive prenatal testing market are F. Hoffmann-La Roche AG, IlluminaInc., Laboratory Corporation of America Holdings, NateraInc., PerkinElmerInc., Quest Diagnostics Incorporated, Agilent TechnologiesInc., BGI Diagnosis, Berry Genomics Co., Ltd., LifeCodexx AG, Myriad GeneticsInc., NIPD Genetics, SequenomInc., Annoroad Gene Technology, Centogene AG, CounsylInc., EUROFINS Genoma Group, Eurofins Scientific, Next Biosciences, Premaitha Health PLC., Ariosa Diagnostics (Roche), Premaitha Health, Beijing Genomics Institute, Yourgene Health PLC., GE Healthcare, Koninklijke Philips N.V., Thermo Fisher ScientificInc., Pacific Biosciences of CaliforniaInc., and QIAGEN N.V. North America was the largest region in the non-invasive prenatal testing market in 2022. Western Europe was the second largest region in the global non-invasive prenatal testing market. The regions covered in the global non-invasive prenatal testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the non-invasive prenatal testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The non-invasive prenatal testing market includes revenue earned by ultrasound detection, fetal cells in maternal blood tests, cell-free DNA in maternal plasma tests, and biochemical screening tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global non-invasive prenatal testing market is segmented - 1) By Type: Consumables, Instruments 2) By End User: Hospital, Diagnostic Labs 3) By Instruments: NGS Systems, PCR Instruments, Microarrays, Ultrasound Devices, Others(Centrifuges, UV Systems, Incubators, Microscopes) 4) By Consumables: Assay Kits &Reagents, Disposables 5) By Application: Trisomy, Microdeletion, Genetics, Rh factor

Haematology analyzers provide complete blood count (CBC) with a three-part differential white blood cell (WBC) count and can detect small cell populations to diagnose rare blood conditions, measure cell morphology. The main products in haematology analyzers and reagents are haematology analyzers, hemostasis analyzers, plasma protein analyzers, haemoglobin analyzers, erythrocyte sedimentation rate analyzers, coagulation analyser, flow cytometers, slide stainers, differential counters, and haematology stains. The hematology analysers are devices that measure the concentration of haemoglobin in a blood sample. The various applications include anemias, blood cancers, hemorrhagic conditions, infection-related conditions, immune system-related conditions, and others that are used by end-users such as specialised research institutes, hospitals, specialised diagnostic centres, and others. The haematology analyzers and reagents market research report is one of a series of new reports from The Business Research Company that provides haematology analyzers and reagents market statistics, including haematology analyzers and reagents industry global market size, regional shares, competitors with a haematology analyzers and reagents market share, detailed haematology analyzers and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the haematology analyzers and reagents industry. This haematology analyzers and reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hematology analyzers and reagents market grew from $4.14 billion in 2022 to $4.56 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hematology analyzers and reagents market is expected to grow from $5.67 billion in 2027 at a CAGR of 5.6%. The rising number of blood donations globally is driving the hematology analyzers and reagents market as hematology analyzers are used to test and screen blood in blood banks. Blood collected from donors through blood donation camps or bloodmobiles is sent to blood banks where hematology analyzers are used to screen and test the blood. These screening tests determine the blood type, analyze the blood plasma and detect infectious diseases. Blood banks are witnessing a huge outflow of blood to hospitals and other end-users and an inflow of blood from blood donations daily. According to the WHO, there was an increase of 7.8 million blood donations from voluntary unpaid donors. As the number of people donating blood increases, the demand for hematology analyzers and reagents increases, thereby driving the market growth. Recalls of defective hematology analyzers are acting as a restraint on the hematology analyzers and reagents market. A product recall is done by the manufacturer or developer of the product as a precautionary measure when safety issues or defects are discovered that can endanger the consumer. A faulty hematology analyzer may provide wrong results and may lead to misdiagnosis, affecting consumer confidence in the analyzers. Regulatory authorities caution healthcare professionals to be aware of the potential for inaccurate diagnostic results with these analyzers and to take appropriate actions including the use of alternative diagnostic testing or confirming analyzer results with manual scanning or estimate of cell counts. For instance, Beckman Coulter Life Sciences recalled its DxH800 and DxH600, and DxH 900 hematology analyzers due to the risk of inaccurate results. Such kind product recalls not only pose a serious safety risk to the public but can also cause significant financial and reputational damage to the companies concerned. Hematology analyzers manufacturers are increasingly investing in the research and development of analyzers with microfluidics technology that use low volumes of samples and reagents. Microfluidics deal with the flow of liquids inside channels as small as a few micrometers. Low reagent consumption by hematology analyzers with microfluidics technology helps reduce operating costs significantly. For instance, the HA5 hematology system from BioSystems is based on microfluidics technology and uses approximately 75% fewer reagents compared to normal hematology analyzers. Also, the respons®3H and respons®5H hematology systems by DiaSys use microfluidics technology and consume 70% fewer reagents. In May 2021, Soulbrain, a South Korean chemicals company, acquired PixCell Medical for an undisclosed amount. The acquisition would support Soulbrain’s growth strategy in the fields of diagnostics and point-of-care testing. PixCell is an Israeli maker of blood test analyzers. Major players in the haematology analyzers market are Abbott, Bio-Rad Laboratories, Horiba, Siemens, Sysmex, BioSystems, Boule, Danaher, Diatron, and Drew Scientific. North America was the largest region in the haematology analyzers market in 2022. Western Europe was the second largest region in the global haematology analyzers market report. The regions covered in the global haematology analyzers and reagents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the haematology analyzers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The haematology analyzers market consists of sales electrolyte analyzer, hemocoagulometer, enzyme standard instrument, blood gas analyzer and immunoturbidimeter. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global haematology analyzers and reagents market is segmented - 1) By Product: Hematology Analysers, Hemostasis Analysers, Plasma Protein Analysers, Hemoglobin Analysers, Erythrocyte Sedimentation Rate Analyser, Coagulation Analyser, Flow Cytometers, Slide Stainers, Differential Counters, Hematology Stains 2) By Applications: Anemias, Blood Cancers, Hemorrhagic Conditions, Infection Related Conditions, Immune System Related Conditions, Other Applications 3) By End User: Specialized Research Institutes, Hospitals, Specialized Diagnostic Centers, Other End Users

Telemedicine services are health care services provided via video chat, phone calls, and text messages. Patients can use telemedicine for physical examination as well as to ask questions regarding health concerns. The main types of telemedicine services are web-based, cloud-based, and on-premises. Cloud-based solutions provide healthcare providers financial, logistical, and functional advantages over in-house client-server systems. Cloud computing provides cost flexibility as well as the potential for cost reductions. The different technologies include store and foreward, real time and is used in teleradiology, telepsychiatry, telepathology, teledermatalogy, telecardiology. The telemedicine services market research report is one of a series of new reports from The Business Research Company that provides telemedicine services market statistics, including telemedicine services industry global market size, regional shares, competitors with a telemedicine services market share, detailed telemedicine services market segments, market trends and opportunities, and any further data you may need to thrive in the telemedicine services industry. This telemedicine services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global telemedicine services market size will grow from $103.06 billion in 2022 to $131.75 billion in 2023 at a compound annual growth rate (CAGR) of 27.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global telemedicine services market size is expected to grow to $262.33 billion in 2027 at a CAGR of 18.8%. Rising cases of COVID 19 infections across the globe is driving the telemedicine services market. As of December 2020, the total number of active cases around the world is around 19,649,961 million and expected to increase until the availability of vaccines. Telemedicine services will provide healthcare services to the COVID 19 affected people as they cannot step out to avail the services. Rising cases of COVID 19 infections across the globe is expected to boost the demand for the telemedicine services market. Breach in the data makes the patients uncomfortable on sharing personal information that would help the physicians to diagnose the patients' health, affecting the telemedicines market negatively. Telemedicine services are provided online or through calls and might not have much security for storing the data, or in some cases the telemedicine companies may use third-party servers to store the customer data to cut down the maintenance cost, which might lead to easy data breaches. For instance, according to Hippa Journal, the official publication of the American Health Information Management Association, the Office for Civil Rights (OCR) of the Department of Health and Human Services (HHS) received 347 reports of healthcare data breaches involving 500 or more records between January 1, 2022, and June 30, 2022. Telemedicine is increasingly being accepted and insurance companies and government-regulated health care programs are increasingly covering telemedicine services in their plans. The governments are probing companies to make changes to the policies to cover the services under their schemes. For instance, in March 2020, in response to the coronavirus outbreak, the US government announced that private insurers will be covering the cost of coronavirus testing and telemedicine services for patients. In April 2022, Patient Square Capital, a US-based healthcare investment firm, acquired SOC Telemed for an undisclosed amount. Through this acquisition, Patient Square Capital will help SOC Telemed to be well-positioned to fulfill the expanding demands of patients, clinicians, and our hospital partners. SOC Telemed is US-based company specializing in telemedicine technology and solutions. Major players in the telemedicine services market are AMD Global Telemedicine Inc., Philips Healthcare, Cisco Systems, Inc., McKesson Corporation, Allscripts Healthcare Solutions Inc., GE Healthcare Ltd., Cerner Corporation, BioTelemetry Inc. and Teladoc. North America was the largest region in the telemedicine services market in 2022. Asia-Pacific was the second largest region in global telemedicine services market. The regions covered in the global telemedicine services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the telemedicine services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The telemedicine services market includes revenues earned by entities by providing teleneuropsychology, telenursing, telepharmacy, and telerehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global telemedicine services market is segmented - 1) By Technology outlook: Store and Foreward, Real time 2) By Application: Teleradiology, Telepsychiatry, Telepathology, Teledermatalogy, Telecardiology 3) By Type: Web-based, Cloud-based, On-premises

Robotic surgery is a form of minimally invasive surgery in which doctors insert a succession of extremely small incisions and tiny surgical equipment into a patient's body. Robotic surgery is the process of performing a surgery using tools that are attached to a robotic arm. It is used to perform surgery with high precision. The robotic surgery services are used in various applications such as general surgery, urological surgery, gynecological surgery, orthopedic surgery, neurosurgery, and others. General surgery is the branch of surgery that deals with the most common surgical procedures. The abdomen, breasts, head and neck, blood arteries, and digestive tract are all treated by general surgeons. They also oversee the treatment of patients who have been wounded, or who have abnormalities or other medical issues that necessitate surgery. The different sectors include hospitals, ambulatory surgery centres (ASCs) and involves various components such as systems, accessories, services. The robotic surgery services market research report is one of a series of new reports from The Business Research Company that provides robotic surgery services market statistics, including robotic surgery services industry global market size, regional shares, competitors with a robotic surgery services market share, detailed robotic surgery services market segments, market trends and opportunities, and any further data you may need to thrive in the robotic surgery services industry. This robotic surgery services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global robotic surgery services market size will grow from $0.86 billion in 2022 to $1.01 billion in 2023 at a compound annual growth rate (CAGR) of 17.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global robotic surgery services market size is expected to grow to $1.8 billion in 2027 at a CAGR of 15.4%. Increase in purchasing power of hospitals and ambulatory care services has helped in the growth of the robotic surgery service market. Hospitals and ambulatory care services are interested in buying latest technologies to provide advanced care to the patients as well as to achieve an edge over their competitors. According to the fourth quarter and full year financial results 2021 of Intuitive Surgical, the robotic surgical giant, the company shipped 385 da Vinci Surgical Systems in fourth quarter, up 18% from the third quarter's 326 units shipped. In 2021, the company shipped 1,347 da Vinci Surgical Systems, a 44% increase from the 936 systems shipped in 2020.Therefore, the purchasing power of hospital and ambulatory care services coupled with the increase in the geriatric population and prevalence of chronic illness have contributed to the growth of robotic surgery services market. Safety concerns regarding the use of robotic surgery services are likely to cause a hindrance to the robotic surgery services market. According to a study on adverse events with robotic-assisted arthroplasty by American Academy of Orthopedic Surgeons, the unexpected robotic arm movement during bone cuts during TKA was the most common adverse event (AE), accounting for 28.9% of all reported AEs, followed by erroneous bone cuts (12.7%) and the robotic component leaking fluid or having residual contaminants (12.3 percent). Accurate bone resections accounted for more than a quarter of all adverse events associated with robotic-assisted PKA. A registration checkpoint being left in the patient accounted for 43.2 percent of all reported adverse events (AEs) in THA patients. Therefore, the safety issues pertaining to robotic surgeries leading to product recalls is expected to hinder the growth of the robotic surgery services market. The image guide navigation system combined with the robotic surgery system offers more possibility to visualize and perform minimally invasive surgery in areas that were earlier difficult, especially the orthopedic surgeries and neurosurgeries. The Mazor X Stealth system by Medtronic, and the NuVasive's Pulse and Excelsius GPS by Globus Medical, among others use image-guided navigation systems to perform spine surgeries, and orthopaedic implant surgeries such as total, partial knee, and hip replacements as they provide the surgeon with 3D experience. The image-guided navigation reduces the radiation effects and patients do not require to take an X-ray after the procedure. These factors state that the image-guided navigation system is expected to be a trend in robotic surgery services. In February 2022, Medtronic PLC., a US-based medical device company, acquired Digital Surgery for an undisclosed amount. Through this acquisition, Digital Surgery will enhance Medtronic's robotic-assisted surgery platform and expand Medtronic's wider range of products. Digital Surgery is a UK-based is a privately held pioneer in digital education and training, data and analytics, and surgical artificial intelligence (AI). Major players in the robotic surgery services market are Intuitive Surgical Inc., Stryker Corporation, Medrobotics Corporation, Johnson & Johnson, Globus medicals, NuVasive, Smith & Nephew PLC., Titan Medical Inc., TransEnterix Inc. and University of Pittsburgh Medical Centre. North America was the largest region in the robotic surgery services market in 2022. Western Europe was the second largest region in the global robotic surgery services market.The regions covered in the global robotic surgery services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the robotic surgery services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The robotic surgery services market includes revenues earned by entities by providing robotic gynaecological services, robotic prostate surgery services, robotic kidney surgery services, and robotic colorectal surgery services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global robotic surgery services market is segmented - 1) By Component: Systems, Accessories, Services 2) By Application: General Surgery, Urological Surgery, Gynecological Surgery, Orthopedic Surgery, Neurosurgery, Other Applications 3) By End-User: Hospitals, Ambulatory Surgery Centers (ASCs)